Video

INDIGO: A Phase 3 Global, Randomized, Double-Blinded Study of Vorasidenib vs Placebo in Patients with Residual or Recurrent Grade 2 Glioma with an IDH1/2 Mutation

Timothy Cloughesy, MD, reviews data from the phase 3 INDIGO trial investigating vorasidenib in patients with residual or recurrent grade 2 glioma with an IDH1 or IDH2 mutation.

Background

  • IDH1/2 mutations occur in most low-grade diffuse gliomas.
  • IDH1/2 hotspot mutations occur in various cancers, including diffuse gliomas.
  • IDH1/2 mutations result in:
    • Overproduction of R-2-hydroxyglutarate
    • Epigenetic dysregulation
    • Impaired cellular differentiation
    • Immunosuppressive tumor microenvironment
  • Vorasidenib is an oral inhibitor of mutant IDH1 and IDH2 specifically designed for brain penetrance.
  • Vorasidenib reduced tumor 2-HG by >90% in resected grade 2/3 non-enhancing diffuse glioma.

Methods

  • Patients enrolled were ≥ 12 years of age with IDH1/2-mutated grade 2 oligodendroglioma or astrocytoma per WHO 2016 guidelines with prior surgery.
  • Patients had measurable non-enhancing disease (≥1 target lesion measuring ≥1 cm x ≥1 cm), confirmed by blinded review.
  • Patients were not in need of immediate chemotherapy or radiotherapy per investigator assessment.
  • Patients were given 40 mg of vorasidenib orally once daily for 28-day cycles vs placebo.
  • Centrally confirmed progressive disease permitted unblinding and crossover.
  • Primary end point was progression-free survival [PFS].
  • Key secondary end point was time from randomization to the initiation of first subsequent anticancer therapy or death because of any cause.

Results

  • Estimated median PFS was 27.7 months for vorasidenib and 11.1 months for placebo, with a hazard ratio of 0.39.
  • Time to next intervention [TTNI] was 17.8 months for placebo and wasn’t reached in the vorasidenib arm.
  • At 24 months, an estimated 83.4% of patients in the vorasidenib arm had not initiated another therapy vs 27.0% of patients in the placebo arm.
  • All subgroups favored vorasidenib.
  • Treatment emergent adverse events:
    • Liver function tests showed increased ALT and AST present in vorasidenib arm and not in placebo.
    • Increased ALT and AST were reversible.
    • Other adverse effects were fairly even matched throughout the study.
    • No fatal treatment emergent adverse events

Conclusions

  • At preplanned interim analysis, vorasidenib demonstrated a significant improvement in:
    • PFS per BIRC
      (HR 0.39, 95% CI 0.27–0.56; P=0.000000067)
    • TTNI
      (HR 0.26, 95% CI 0.15–0.43; P=0.000000019)
  • Diffuse gliomas with IDH1/2 mutations are not curable with current therapies and infiltrate the brain in the absence of treatment.
  • Vorasidenib is an oral inhibitor of the mutant IDH1/2 enzymes with proven brain penetrance.
  • Treatment with vorasidenib significantly improved imaging-based PFS and TTNI with a manageable safety profile in patients who were not in need of immediate chemotherapy or radiotherapy​.

Mellinghoff IK, van den Bent MJ, Blumenthal DT et al. INDIGO: a Phase 3 global, randomized, double-blinded study of vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation. Abstract presented at: 2023 ASCO Annual Meeting, June 2-6, 2023.

Funding supported by Servier Pharmaceuticals. Content independently developed by OncLive.

Related Videos
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Key Data from the CYTO-PV and MAJIC-PV Studies: Evaluating Ruxolitinib in Polycythemia Vera
Lorenza Rimassa, MD
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Nicholas P. McAndrew, MD, MSCE
Phase 1/2 ARROS-1 study of zidesamtinib (NVL-520) in ROS1 fusion-positive solid tumors
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC